African Health Sciences
Makerere University Medical School
Vol. 16, No. 4, 2016, pp. 1089-1093
Bioline Code: hs16140
Full paper language: English
Document type: Research Article
Document available free of charge
African Health Sciences, Vol. 16, No. 4, 2016, pp. 1089-1093
© Copyright 2016 - African Health Sciences
Low sero-prevalence of hepatitis delta antibodies in HIV/ hepatitis B co-infected patients attending an urban HIV clinic in Uganda.|
Katwesigye, Elizabeth; Seremba, Emmanuel; Semitala, Fred & Ocama, Ponsiano
Background: Co-infection with hepatitis B (HBV) and hepatitis D (HDV) is common among human immunodeficiency virus
(HIV) infected individuals in developing countries and it aggressively accelerates progression of liver disease to cirrhosis and
other complications. There is scarcity of data on HDV in sub-Saharan Africa .We investigated the sero-prevalence and factors
associated with HDV antibody among HIV/HBV co-infected patients attending a large urban HIV clinic in Uganda.
Methods: We screened 189 HIV/HBV co-infected individuals for anti-HDV immunoglobulin G (IgG) and performed logistic
regression to determine the associated factors. Socio-demographic, clinical data, immunological status, and liver fibrosis (as determined
by the Aspartate transaminase to platelet ratio index and transient elastography) were included.
Results: Participants were predominately young and of sound immunologic status (median age 40 years, median CD4 440
cells/μl). 98% were on ART regimens containing anti-HBV active medications (95.2% were on TDF/3TC while 4.8% on 3TC
containing regimen). Median duration on ART was 36 months (IQR 22-72). Anti-HDV was detected in 6/198, 3.2% (95% CI
1.14-6.92%), associated with male gender and a duration of more than 5 years since HIV diagnosis.
Conclusions: The sero-prevalence of HDV antibodies among the HIV/HBV co-infected patients is low in a Ugandan urban cohort.
Co-infection in Uganda; hepatitis delta antibodies; hepatitis B virus; HIV